Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines

Prostate

Volumn 71, Issue 13, 2011, Pages 1466-1479

  Barboro, Paola ^a   Repaci, Erica ^a   Ferrari, Nicoletta ^a   Rubagotti, Alessandra ^a,b   Boccardo, Francesco ^a,b   Balbi, Cecilia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

4 hydroxy tamoxifen; androgen receptor; bicalutamide; confocal laser scanning microscopy; heterogeneous nuclear ribonucleoprotein K; nuclear matrix; prostate cancer

Indexed keywords

AFIMOXIFENE; ANDROGEN RECEPTOR; BICALUTAMIDE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; NUCLEAR MATRIX PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL COMPARTMENTALIZATION; CELL FRACTIONATION; CELL NUCLEUS MATRIX; CELL VIABILITY; CONFOCAL MICROSCOPY; IMMUNODETECTION; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 79959289248     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21366     Document Type: Article

References (49)

1. Wirth MP, Hakenberg OW, Froehner M,. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007; 51 (2): 306-314. (Pubitemid 44937805)
2. Di Lorenzo G, Autorino R, Perdonà S, De Placido S,. Management of gynaecomastia in patients with prostate cancer: A systematic review. Lancet Oncol 2005; 6 (12): 972-979. (Pubitemid 41685230)
3. Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F,. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005; 23 (4): 808-815. (Pubitemid 46224180)
4. Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Cortellini P, Martorana G, Lapini A, Boccardo F,. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 2010; 57 (2): 238-245.
5. Van Poppel H,. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150mg monotherapy in patients with prostate cancer: A randomised, placebo-controlled, dose-response study. Eur Urol 2007; 52 (1): 115. (Pubitemid 46805191)
6. Zink D, Fisher AH, Nickerson JA,. Nuclear structure in cancer cells. Nat Rev Cancer 2004; 4 (9): 677-687. (Pubitemid 39215066)
7. Stein GS, Stein JL, Lian JB, Van Wijnen AJ, Montecino M, Javed A, Zaidi SK, Young D, Choi JY, Pockwinse S,. Nuclear microenvironments: An architectural platform for the convergence and integration of transcriptional regulatory signals. Eur J Histochem 2004; 48 (1): 65-76. (Pubitemid 38524337)
8. Barrack ER, Coffey DS,. The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem 1980; 255 (15): 7265-7275. (Pubitemid 11232887)
9. Leman ES, Getzenberg RH,. Nuclear matrix proteins as biomarkers in prostate cancer. J Cell Biochem 2002; 86 (2): 213-223. (Pubitemid 34743378)
10. Boccardo F, Rubagotti A, Carmignani G, Romagnoli A, Nicolò G, Barboro P, Parodi S, Patrone E, Balbi C,. Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. Prostate 2003; 55 (4): 259-264. (Pubitemid 36618184)
11. Barboro P, Rubagotti A, Boccardo F, Carnemolla B, Darrigo C, Patrone E, Balbi C,. Nuclear matrix protein expression in prostate cancer: Possible prognostic and diagnostic applications. Anticancer Res 2005; 25 (6B): 3999-4004. (Pubitemid 41665177)
12. Bomsztyk K, Denisenko O, Ostrowski J,. hnRNP K: One protein multiple processes. Bioessays 2004; 26 (6): 629-638. (Pubitemid 38758340)
13. Chen LC, Hsueh C, Tsang NM, Liang Y, Chang KP, Hao SP, Yu JS, Chang YS,. Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin Cancer Res 2008; 14 (12): 3807-3813.
14. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI,. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006; 95 (7): 921-927. (Pubitemid 44498109)
15. Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R, Naaby-Hansen S,. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 2004; 23 (9): 1693-1703. (Pubitemid 38445161)
16. Wang LG, Johnson EM, Kinoshita Y, Babb JS, Buckley MT, Liebes LF, Melamed J, Liu XM, Kurek R, Ossowski L, Ferrari AC,. Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex. Cancer Res 2008; 68 (8): 2678-2688. (Pubitemid 351556265)
17. Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D, Adam RM, Rubin MA, Raychaudhuri P, De Benedetti A, Freeman MR,. Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res 2009; 69 (6): 2210-2218.
18. Barboro P, Repaci E, Rubagotti A, Salvi S, Boccardo S, Spina B, Truini M, Introini C, Puppo P, Ferrari N, Carmignani G, Boccardo F, Balbi C,. Heterogeneous nuclear ribonucleoprotein K: Altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer 2009; 100 (10): 1608-1616.
19. Kim D, Tucker PW,. A regulated nucleocytoplasmic shuttle contributes to Bright's function as a transcriptional activator of immunoglobulin genes. Mol Cell Biol 2006; 26 (6): 187-201.
20. Barboro P, D'Arrigo C, Diaspro A, Mormino M, Alberti I, Parodi S, Patrone E, Balbi C,. Unraveling the organization of the internal nuclear matrix: RNA-dependent anchoring of NuMA to a lamin scaffold. Exp Cell Res 2002; 279 (2): 202-218. (Pubitemid 35217549)
21. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, Orecchia P, Zardi L, Righetti PG,. Blue silver: A very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004; 25 (9): 1327-1333. (Pubitemid 38801651)
22. Barboro P, Rubagotti A, Orecchia P, Spina B, Truini M, Repaci E, Carmignani G, Romagnoli A, Introini C, Boccardo F, Carnemolla B, Balbi C,. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: Potential to improve diagnosis and prognosis. Cell Oncol 2008; 30 (1): 13-26. (Pubitemid 351161036)
23. Heukeshoven J, Dernick R,. Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis 1988; 9 (1): 28-32.
24. Laemmli UK,. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227 (5259): 680-685.
25. Alberti I, Barboro P, Barbesino M, Sanna P, Pisciotta L, Parodi S, Nicolò G, Boccardo F, Galli S, Patrone E, Balbi C,. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. J Cell Biochem 2000; 79 (3): 471-485.
26. Barboro P, D'Arrigo C, Repaci E, Bagnasco L, Orecchia P, Carnemolla B, Patrone E, Balbi C,. Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: Identification of differentially expressed and MAR-binding proteins. Exp Cell Res 2009; 315 (2): 226-239.
27. Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, Stanley EF,. A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: Analysis by quantitative immunocolocalization. J Neurosci 2004; 24 (16): 4070-4081. (Pubitemid 38544233)
28. Manders EMM, Verbeek FJ, Aten JA,. Measurement of co-localization of objects in dual-colour confocal images. J Microsc 1993; 169 (3): 375-382. (Pubitemid 23119681)
29. Bolte S, Cordelières FP,. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 2006; 224 (Pt 3): 213-232. (Pubitemid 46010930)
30. Sezgin M, Sankur B,. Survey over image thresholding techniques and quantitative performance evaluation. J Electronic Imaging 2004; 13 (1): 146-165.
31. Powell SM, Brooke GN, Whitaker HC, Reebye V, Gamble SC, Chotai D, Dart DA, Belandia B, Bevan CL,. Mechanisms of androgen receptor repression in prostate cancer. Biochem Soc Trans 2006; 34 (Pt 6): 1124-1127. (Pubitemid 46769002)
32. Whitaker HC, Hanrahan S, Totty N, Gamble SC, Waxman J, Cato AC, Hurst HC, Bevan CL,. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens. Clin Cancer Res 2004; 10 (21): 7392-7401. (Pubitemid 39489890)
33. Quéro L, Giocanti N, Hennequin C, Favaudon V,. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells. Prostate 2010; 70 (4): 401-411.
34. Saitoh M, Takayanagi R, Goto K, Fukamizu A, Tomura A, Yanase T, Nawata H,. The presence of both the amino- and carboxyl-terminal domains in the AR is essential for the completion of a transcriptionally active form with coactivators and intranuclear compartmentalization common to the steroid hormone receptors: A three-dimensional imaging study. Mol Endocrinol 2002; 16 (4): 694-706. (Pubitemid 34297740)
35. Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, Moran T, Mikic I, Price JH, Mancini MA,. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem 2006; 98 (4): 770-788. (Pubitemid 43993395)
36. Malyavantham KS, Bhattacharya S, Barbeitos M, Mukherjee L, Xu J, Fackelmayer FO, Berezney R,. Identifying functional neighborhoods within the cell nucleus: Proximity analysis of early S-phase replicating chromatin domains to sites of transcription, RNA polymerase II, HP1gamma, matrin 3 and SAF-A. J Cell Biochem 2008; 105 (2): 391-403.
37. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP,. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277 (29): 26321-26326. (Pubitemid 34967123)
38. Shi L, Ko S, Kim S, Echchgadda I, Oh TS, Song CS, Chatterjee B,. Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein- regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1. J Biol Chem 2008; 283 (52): 36474-36485.
39. Benelli R, Monteghirfo S, Balbi C, Barboro P, Ferrari N,. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 2009; 124 (12): 2989-2996.
40. Ostrowski J, Schullery DS, Denisenko ON, Higaki Y, Watts J, Aebersold R, Stempka L, Gschwendt M, Bomsztyk K,. Role of tyrosine phosphorylation in the regulation of the interaction of heterogenous nuclear ribonucleoprotein K protein with its protein and RNA partners. J Biol Chem 2000; 275 (5): 3619-3628. (Pubitemid 30083072)
41. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK,. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 2000; 14 (8): 1162-1174. (Pubitemid 32260478)
42. Bouchal J, Kolár Z, Mad'arová J, Hlobilková A, von Angerer E,. The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP. Biochem Pharmacol 2002; 63 (6): 1177-1181. (Pubitemid 34267033)
43. Boccardo F, Medicina D, Galmozzi F, Emionite L, Lo Casto M,. 4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells in vitro. Anticancer Res 2005; 25 (6B): 4277-4280. (Pubitemid 41665216)
44. O'Brian C, Liskamp RM, Solomon DH, Weinstein IB,. Inhibition of protein kinase C by Tamoxifen. Cancer Res 1985; 45 (6): 2462-2465. (Pubitemid 15024408)
45. Schullery DS, Ostrowski J, Denisenko ON, Stempka L, Shnyreva M, Suzuki H, Gschwendt M, Bomszty K,. Regulated interaction of protein kinase Cδ with the heterogeneous nuclear ribonuclearprotein K protein. J Biol Chem 1999; 274 (21): 15101-15109.
46. Saltzstein D, Sieber P, Morris T, Gallo J,. Prevention and management of bicalutamide-induced gynecomastia and breast pain: Randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005; 8 (1): 75-83.
47. Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S,. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: A randomised, placebo-controlled, dose-response study. Eur Urol 2007; 52 (1): 106-114.
48. Boccardo F, Rubagotti A, Conti G, Potenzoni D, Manganelli A, Del Monaco D,. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer Chemother Pharmacol 2005; 56 (4): 415-420. (Pubitemid 41095405)
49. Lau KM, LaSpina M, Long J, Ho SM,. Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000; 60 (12): 3175-3182. (Pubitemid 30407914)